Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Verapamil Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg

NCT00648050
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Rate Control, Ablation Therapy, Rhythm control
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00647673
View directory record Official record
Conditions
Healthy
Interventions
Verapamil HCL Extended-Release Capsules 300 mg, Verelan® PM Extended-Release Capsules 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00649805
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

NCT01505179
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 3 Interventional

Pharmacotherapy of Treatment-Resistant Mania

NCT00518947
View directory record Official record
Conditions
Mania
Interventions
Lithium, verapamil, verapamil plus lithium
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 4 Interventional Results available

The Intra-arterial Vasospasm Trial

NCT01996436
View directory record Official record
Conditions
Cerebral Vasospasm
Interventions
Nicardipine, Verapamil, Nicardipine + Verapamil + Nitroglycerin
Drug
Lead sponsor
Peng Roc Chen, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Manhasset, New York • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Verapamil for Neuroprotection in Stroke

NCT03347786
View directory record Official record
Conditions
Ischemic Stroke
Interventions
10 mg Intra-arterial Verapamil, 20 mg Intra-arterial Verapamil
Drug
Lead sponsor
Global Neurosciences Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Atlantic City, New Jersey • Langhorne, Pennsylvania • Upland, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 1, 2026, 8:23 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 1, 2026, 8:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574
View directory record Official record
Conditions
Type 1 Diabetes, New Onset
Interventions
Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
9 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Not applicable Interventional Results available

Arthrex Eclipse™ Shoulder Prosthesis

NCT01790113
View directory record Official record
Conditions
Osteoarthritis
Interventions
Univers™, Eclipse™ Total Shoulder Replacement
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
21 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Sun City, Arizona • Redwood City, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

NCT04008186
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed No phase listed Observational

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

NCT06177691
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 1, 2026, 8:23 PM EDT
Not listed Phase 1 Interventional

Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor

NCT05745337
View directory record Official record
Conditions
Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 3 Interventional Results available

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

NCT04233034
View directory record Official record
Conditions
Type1 Diabetes
Interventions
HCL, verapamil 120mg tablet, non-HCL, placebo
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

NCT02111317
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K
Interventions
ASP015K, verapamil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 1, 2026, 8:23 PM EDT
Withdrawn Phase 4 Interventional

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

NCT06107829
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Valbenazine Oral Capsule
Drug
Lead sponsor
Stephen Ruedrich
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional

INVEST: INternational VErapamil SR Trandolapril STudy

NCT00133692
View directory record Official record
Conditions
Hypertension, Coronary Artery Disease
Interventions
Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 1 Interventional

Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.

NCT02912663
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil and Magnesium Sulfate, Placebo
Drug · Other
Lead sponsor
Justin Fraser
Other
Eligibility
18 Years to 101 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Early Phase 1 Interventional

Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

NCT05847413
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Verapamil
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 1, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional Results available

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

NCT00589303
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 1, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Tinnitus With Migraine Medications

NCT04404439
View directory record Official record
Conditions
Tinnitus, Subjective, Tinnitus
Interventions
Nortriptyline + Topiramate, Verapamil + Paroxetine, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 1, 2026, 8:23 PM EDT